Format

Send to

Choose Destination
Open Biol. 2017 Sep;7(9). pii: 170070. doi: 10.1098/rsob.170070.

Progress and prospects of early detection in lung cancer.

Author information

1
North West Lung Centre, University Hospital South Manchester, Manchester, UK.
2
Cancer Research UK Lung Cancer Centre of Excellence at Manchester and University College London, UK.
3
Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, UK.
4
Manchester Collaborative Centre for Inflammation Research, University of Manchester, Manchester, UK.
5
Cancer Research UK Lung Cancer Centre of Excellence at Manchester and University College London, UK caroline.dive@cruk.manchester.ac.uk.

Abstract

Lung cancer is the leading cause of cancer-related death in the world. It is broadly divided into small cell (SCLC, approx. 15% cases) and non-small cell lung cancer (NSCLC, approx. 85% cases). The main histological subtypes of NSCLC are adenocarcinoma and squamous cell carcinoma, with the presence of specific DNA mutations allowing further molecular stratification. If identified at an early stage, surgical resection of NSCLC offers a favourable prognosis, with published case series reporting 5-year survival rates of up to 70% for small, localized tumours (stage I). However, most patients (approx. 75%) have advanced disease at the time of diagnosis (stage III/IV) and despite significant developments in the oncological management of late stage lung cancer over recent years, survival remains poor. In 2014, the UK Office for National Statistics reported that patients diagnosed with distant metastatic disease (stage IV) had a 1-year survival rate of just 15-19% compared with 81-85% for stage I.

KEYWORDS:

NLST trial; low-dose CT screening; lung cancer

PMID:
28878044
PMCID:
PMC5627048
DOI:
10.1098/rsob.170070
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center